Releases
MRSN
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Mersana (MRSN) stock and general news. This information may help you make smarter investment decisions.
About MRSN
Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing antibody drug conjugates (ADCs). The Company’s platforms include Dolaflexin and Dolasynthen. Its product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company’s early stage programs include B7-H4-targeted Dolasynthen ADC, XMT-1660, as well as candidates leveraging the Immunosynthen platform. UpRi is an ADC utilizing the Company’s Dolaflexin platform and targeting NaPi2b, which is an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. XMT-1592 uses the Company’s Dolasynthen platform and targets NaPi2b.